| 摘要: |
| ［摘要］ 目的 观察培美曲塞二线单药治疗非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法 选择经病理及细胞学诊断为NSCLC患者25例，均有可测量和评估的病灶。给予培美曲塞500 mg/m2加入0.9%氯化钠100 ml中静滴，21 d为1周期，连用2～4周期。结果 总有效率为8%，临床获益率为72%。主要毒副反应是Ⅰ～Ⅱ度骨髓抑制。结论 培美曲塞治疗复发、转移的NSCLC有较好的临床获益率，不良反应小，值得临床推广应用。 |
| 关键词: 非小细胞肺癌 培美曲塞 疗效 毒副反应 |
| DOI：10.3969/j.issn.1674-3806.2013.09.15 |
| 分类号:R 743 |
| 基金项目: |
|
| Clinical observation of pemetrexed in second-line treatment of non-small cell lung cancer |
|
HE Mei, WU Yu-zhi,LIU Wei-ping,et al.
|
|
Department of Respiration Diseases, Shanxi People′s Hospital,Taiyuan 030012, China
|
| Abstract: |
| ［Abstract］ Objective To observe the clinical effect and toxicity of pemetrexed monotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Twenty-five patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received pemetrexed 500 mg/m2 on d1, intravenously every 21 days as one cycle and the effects were evaluated after 2～4 cycles.Results The total response rate was 8%. The clinical benefit rate was 72%. The main toxicity was Grade Ⅰ～Ⅱ hematological toxicity.Conclusion Pemetrexed is an effective therapy for the patients with advanced NSCLC. Its efficacy is better,the toxicities can be tolerated and is worth clinical promotion. |
| Key words: Non-small cell lung cancer（NSCLC） Pemetrexed Clinical effect Toxicity |
